Pichia kudriavzevii (Saccharomycetaceae) Yeast

Pichia kudriavzevii is a remarkable non-conventional yeast species, formerly known as Candida krusei, that occupies a unique dual role in both industrial biotechnology and human health. It is most notably recognized for its exceptional multi-stress tolerance, making it a flagship species for industrial biomanufacturing and food fermentation. Simultaneously, it acts as an opportunistic pathogen with intrinsic resistance to fluconazole, posing significant clinical challenges. Recent cutting-edge research has revealed its potent probiotic, antimicrobial, and antifungal properties, with promising applications in combating oral pathogens, producing functional foods, and developing controlled-release drug delivery systems.

---

1. Taxonomic Insights

Species: Pichia kudriavzevii Boidin, Pignal & Besson

Family: Saccharomycetaceae (Phylum Ascomycota, Class Saccharomycetes)

The Saccharomycetaceae family comprises the true yeasts, a diverse group of unicellular fungi characterized by their ability to ferment sugars and reproduce by budding. This family includes some of the most economically and scientifically significant microorganisms, including the model organism Saccharomyces cerevisiae. Pichia kudriavzevii, formerly classified in the genus Issatchenkia, has undergone significant taxonomic revision based on phylogenetic analyses.

Taxonomic Note: Pichia kudriavzevii is the accepted teleomorph (sexual stage) name for the species formerly and still widely known in clinical contexts as Candida krusei. This yeast was originally described by Castellan in 1910 as Candida krusei. The connection between the anamorph (asexual stage, Candida krusei) and teleomorph (sexual stage, Pichia kudriavzevii) was established later. Understanding this dual nomenclature is critical for navigating both the clinical literature, where Candida krusei predominates, and the biotechnological literature, where Pichia kudriavzevii is increasingly used.

Related Species from the Same Genus or Family:

· Pichia pastoris (Komagataella phaffii): A renowned yeast species used extensively for recombinant protein expression, known for its ability to grow to high cell densities and perform complex eukaryotic post-translational modifications.

· Saccharomyces cerevisiae (Baker's Yeast): The most well-studied eukaryotic model organism and industrial workhorse, used in baking, brewing, and bioethanol production, though less stress-tolerant than P. kudriavzevii.

· Candida albicans: The most clinically significant opportunistic fungal pathogen, frequently causing candidiasis in immunocompromised individuals, with different resistance profiles compared to P. kudriavzevii.

· Wickerhamomyces anomalus (formerly Pichia anomala): Another non-conventional yeast with probiotic, antimicrobial, and industrial applications, known for its killer toxin production.

---

2. Common Names

Scientific Name: Pichia kudriavzevii Boidin, Pignal & Besson | Clinical Name (Anamorph): Candida krusei (Castell.) Berkhout | Common/Industrial Names: No widely established common names; often referred to simply as "Pichia yeast" or in clinical contexts as "Candida krusei" | Regional/Trade Names: Occasionally referred to by strain designations such as YK116, MYSSBYPS10, or OQ119615 in research contexts | Fermentation Industry: Sometimes colloquially called "stress yeast" or "tolerant yeast" due to its exceptional stress resistance

---

3. Medicinal and Biotechnological Uses

Primary Actions (Probiotic/Biotechnological): Probiotic, Antifungal, Antibacterial, Antibiofilm, Antioxidant, Anti-ochratoxigenic (mycotoxin reduction), Postbiotic (cell wall-based delivery).

Primary Actions (Clinical/Pathological): Opportunistic Pathogen, Intrinsically Antifungal-resistant, Biofilm former, Virulence factor producer.

Secondary Actions: Flavor enhancement (ester production), Controlled-release agent, Biocontrol agent (postharvest), Stress tolerance (thermotolerant, acidotolerant, osmotolerant).

Medicinal/Industrial Preparations:

The applications of P. kudriavzevii are highly context-dependent, utilizing either viable cells, heat-killed cells, or extracted metabolites.

· Viable Yeast Cells: Used as a probiotic, as a starter culture in fermentation (vinegar, traditional fermented foods), and as a biocontrol agent against plant pathogens.

· Heat-Killed Cells: Used as postbiotics with enhanced safety profiles, showing potent in vivo antibacterial activity.

· Cell Wall Derivatives: The yeast cell wall (β-glucans, mannoproteins) is extracted and cross-linked with polymers like alginate and chitosan to create controlled-release microcapsules.

· Crude Extract (Ethyl Acetate Extract): A concentrated extract of secondary metabolites (PKEAE) with potent antibacterial, antibiofilm, and antifungal properties.

· Volatile Organic Compounds (VOCs): The natural gas emissions from the yeast, which can inhibit the growth of other fungi and bacteria.

---

4. Phytochemicals and Bioactive Compounds Specific to the Yeast and Their Action

Unlike plants, yeasts produce bioactive secondary metabolites rather than classical phytochemicals.

· Ethyl Acetate and other Esters: Produced in high quantities, these are responsible for the fruity aroma in fermented products. Ethyl acetate exhibits Antimicrobial activity.

· Fatty Acids (Oleic acid, Linoleic acid, Palmitic acid): These membrane lipids contribute to Antimicrobial and Anti-inflammatory effects.

· Volatile Organic Compounds (Decane, 1,2-Benzenedicarboxylic acid monoester): These gas-phase metabolites exhibit Antibacterial activity against pathogens like Pectobacterium carotovorum.

· β-Glucans and Mannoproteins (Cell Wall Components): These polysaccharides possess Immunomodulatory, Antioxidant, and Controlled-release properties when used as encapsulating agents.

· Enzymes (Esterases, Lipases, Proteases, Glucanases): These enzymes are responsible for the yeast's industrial functions, including flavor compound synthesis (esterases) and virulence (phospholipases, proteinases).

· Secondary Metabolites (from Ethyl Acetate Extract - PKEAE): The crude ethyl acetate extract contains a complex mixture of unidentified bioactive molecules that disrupt bacterial cell membranes, inhibit biofilm formation, and are safe on normal epithelial cells.

· Other Metabolites (Phenylethyl acetate, Isoamyl acetate): Aroma compounds with potential antimicrobial properties.

---

5. Traditional and Industrial Applications Covering the Uses

Food Fermentation and Flavor Enhancement (Industrial)

Formulation: Viable yeast cells as a starter culture or adjunct.

Preparation & Use: P. kudriavzevii is used in the solid-state fermentation of Zhenjiang aromatic vinegar and other traditional fermented foods. It is inoculated into the fermentation substrate (e.g., vinegar Pei) alongside other microorganisms.

Reasoning: The yeast exhibits superior tolerance to high temperatures (40°C+), high acetic acid concentrations (up to 6%), and high ethanol levels, which are lethal to many other yeasts. It significantly enhances the production of fruity esters (ethyl acetate, phenylethyl acetate, isoamyl acetate) by modulating the fungal community structure, improving the aroma profile of the final product.

Probiotic and Postbiotic for Gut Health

Formulation: Viable or heat-killed yeast cells; triple-layer microcapsules.

Preparation & Use: Yeast isolates from fermented foods (e.g., dosa batter, sprouted soybeans) are characterized for probiotic properties. The yeast cells are encapsulated in alginate-chitosan constructs using the yeast cell wall as a cross-linking agent for targeted delivery.

Reasoning: P. kudriavzevii demonstrates over 68% survival in acidic gastric pH and bile conditions, with no sensitivity to simulated gastric juice. It exhibits high autoaggregation (>90%) and cell surface hydrophobicity, essential for gut adhesion. Heat-killed cells show enhanced safety and superior in vivo anti-S. aureus activity (89.71%) compared to viable cells (74.39%). The triple-layer microcapsule enables controlled release of the bioactive contents specifically in the gut.

Antifungal and Antibacterial Biocontrol

Formulation: Viable yeast cells; Volatile Organic Compounds (VOCs).

Preparation & Use: The yeast is cultured and applied as a bio-fungicide against postharvest pathogens of fruits and vegetables, such as soft rot in carrots.

Reasoning: P. kudriavzevii exhibits potent antagonistic activity against fungal pathogens including Macrophomina phaseolina (69.14% growth inhibition), Aspergillus niger (64.72%), and Fusarium oxysporum (68.60%). The VOCs alone, particularly decane and 1,2-benzenedicarboxylic acid monoester, inhibit fungal growth by 44-56%, providing a natural alternative to chemical fungicides.

Antimicrobial Agent against Oral Pathogens (Modern Research)

Formulation: Ethyl acetate extract of P. kudriavzevii (PKEAE).

Preparation & Use: The extract is prepared from yeast isolated from the healthy human oral cavity and is applied as a potential mouthwash or dental therapeutic.

Reasoning: PKEAE demonstrates potent antibacterial activity against Streptococcus mutans and Streptococcus salivarius, the primary cariogenic bacteria causing dental caries. It exhibits minimum inhibitory concentration (MIC) values of 0.025-0.05 mg/ml and minimum bactericidal concentration (MBC) values of 0.05-0.1 mg/ml, outperforming some pharmaceutical preparations. It also shows significant inhibition of biofilm formation and causes major structural degeneration of bacterial cells. Crucially, it is safe on normal oral epithelial cells, indicating a strong safety profile.

Anti-ochratoxigenic Agent (Mycotoxin Reduction)

Formulation: Viable and heat-killed yeast cells.

Preparation & Use: The yeast is applied to food products to reduce ochratoxin contamination.

Reasoning: HPLC-based analysis confirms both viable and heat-killed cells exhibit potent anti-ochratoxigenic activity, reducing the levels of this harmful mycotoxin produced by Aspergillus and Penicillium species.

---

6. Research Recipes, Fermentation Protocols, and Preparations

Antibacterial Ethyl Acetate Extract (PKEAE)

Purpose: Laboratory preparation for antibacterial testing against oral pathogens.

Preparation & Use:

1. Culture Pichia kudriavzevii isolate (e.g., OQ119615) in appropriate liquid medium (e.g., Yeast Extract Peptone Dextrose broth) under shaking conditions.

2. Harvest the culture and extract with ethyl acetate.

3. Concentrate the extract under reduced pressure to obtain the crude residue.

4. Dissolve in a suitable solvent (e.g., DMSO) for antimicrobial assays. Note: This is a laboratory research preparation, not a home remedy.

Triple-Layer Microcapsule for Controlled Release

Purpose: For targeted delivery of postbiotics or other bioactives.

Preparation & Use:

1. Isolate and purify the yeast cell wall from Pichia kudriavzevii cells.

2. Cross-link the yeast cell wall with alginate and chitosan using standard ionic gelation methods.

3. Incorporate the desired bioactive compound into the matrix.

4. The construct enables targeted delivery and controlled release of the entrapped compound under simulated gastrointestinal conditions.

Probiotic Culture Preparation

Purpose: For fermentation or probiotic supplementation (research/food production).

Preparation & Use:

1. Activate the Pichia kudriavzevii strain (e.g., MYSSBYPS10) from frozen stock on appropriate agar.

2. Inoculate a single colony into sterile growth medium (e.g., YPD broth) and incubate at 30°C with shaking for 24-48 hours.

3. Harvest cells by centrifugation, wash with sterile saline, and resuspend to the desired concentration.

4. The viable cell suspension can be used as a starter culture for fermentation or as a probiotic supplement in controlled studies.

---

7. In-Depth Bioactive Profile and Clinical Significance of Pichia kudriavzevii (Candida krusei)

Introduction

Pichia kudriavzevii stands as one of the most fascinating and paradoxical microorganisms in contemporary science. It is a yeast of extremes: an industrial champion and a clinical challenge. In the biotechnological arena, it is celebrated as a flagship non-conventional yeast, possessing an extraordinary capacity to thrive under multiple severe stresses that would cripple conventional workhorses like Saccharomyces cerevisiae. This innate resilience has made it a valuable asset for the bioeconomy, driving innovation in food fermentation, biofuel production, and waste valorization. Concurrently, as its anamorph Candida krusei, it has emerged as a significant opportunistic fungal pathogen, intrinsically resistant to the common antifungal fluconazole and capable of forming robust biofilms on medical devices. This Janus-faced nature makes P. kudriavzevii a critical subject of study, requiring a sophisticated understanding that spans both its industrial utility and its pathogenic mechanisms. Recent breakthroughs in 2025 and 2026 have dramatically expanded its therapeutic potential, revealing its probiotic properties, its potent antibacterial activity against cariogenic oral pathogens, its anti-ochratoxigenic effects, and its application as a controlled-release agent in cutting-edge microencapsulation technologies.

1. Multi-Stress Tolerance Mechanisms (The Industrial and Probiotic Backbone)

Key Traits: Thermotolerance (growth at 40-45°C), acidotolerance (pH 2.0 survival), ethanol tolerance (up to 10-15%), acetic acid tolerance (up to 6%), osmotic tolerance (high sugar/salt), and tolerance to furanic/phenolic inhibitors.

Quantitative Profile: Over 68% survival in simulated gastric juice (pH 2.0 with pepsin) and bile conditions. Over 90% autoaggregation and cell surface hydrophobicity.

Actions and Clinical Relevance:

· Industrial Biomanufacturing (Flagship Application): P. kudriavzevii's exceptional multi-stress tolerance makes it a flagship species for advancing the bioeconomy. Unlike Saccharomyces cerevisiae, which requires extensive genetic modification to survive harsh industrial conditions, P. kudriavzevii possesses innate resilience. This allows it to thrive in high-temperature fermentations (reducing cooling costs), tolerate high concentrations of inhibitory compounds (e.g., furans and phenolics from lignocellulosic biomass), and survive extreme pH and osmotic conditions. These traits make it an attractive candidate for producing biofuels, biochemicals, and other industrial products without the need for costly genetic engineering.

· Probiotic Viability: The same stress tolerance mechanisms that enable industrial robustness also underpin its probiotic potential. To function as an effective probiotic, a microorganism must survive the harsh conditions of the upper gastrointestinal tract, including acidic gastric pH, bile salts, and digestive enzymes. P. kudriavzevii demonstrates over 68% survival in these conditions, comparable to or exceeding many established probiotic bacteria. Its high autoaggregation and hydrophobicity facilitate adhesion to the intestinal epithelium, a key requirement for colonization and immunomodulation. Its non-hemolytic and non-gelatinase activity confirms its safety profile.

2. Antimicrobial and Antibiofilm Arsenal (Recent Breakthroughs 2025-2026)

Key Preparations: Ethyl acetate extract (PKEAE), Volatile Organic Compounds (VOCs), Heat-killed cells.

Quantitative Profile (Antibacterial): MIC of 0.025-0.05 mg/ml and MBC of 0.05-0.1 mg/ml against S. mutans. >90% inhibition of biofilm formation.

Quantitative Profile (Antifungal): 69.14% growth inhibition of M. phaseolina, 64.72% of A. niger, 68.60% of F. oxysporum. VOCs inhibit 44-56% of fungal growth.

Actions and Clinical Relevance:

· Anti-oral Pathogen Activity (2025 Breakthrough): A landmark 2025 study isolated P. kudriavzevii for the first time from the healthy human oral cavity and demonstrated that its ethyl acetate extract (PKEAE) exhibits potent antibacterial activity against Streptococcus mutans and S. salivarius, the primary bacteria responsible for dental caries. The MIC values of 0.025-0.05 mg/ml indicate potent activity, and the extract outperformed some conventional pharmaceutical preparations. Crucially, PKEAE significantly inhibited biofilm formation, the protective matrix that makes oral bacteria highly resistant to treatment. Scanning electron microscopy (SEM) revealed complete morphological degeneration of S. mutans cells after treatment. Cytotoxicity assays confirmed the extract is safe on normal oral epithelial cells, positioning it as a promising natural alternative to chemical mouthwashes and antibiotics for preventing tooth decay.

· Antifungal and Biocontrol Activity (2025-2026 Studies): P. kudriavzevii isolated from traditional fermented foods (e.g., dosa batter) shows potent antifungal activity against major plant pathogens. The mechanism involves both direct contact inhibition and the action of volatile organic compounds (VOCs). The VOCs alone can inhibit fungal growth by 44-56% without direct contact, suggesting a gaseous mode of action. This makes the yeast a promising biocontrol agent for postharvest diseases of fruits and vegetables, reducing reliance on chemical fungicides.

· Antioxidant and Anti-ochratoxigenic Activity: The yeast demonstrates significant antioxidant properties. Both viable and heat-killed cells effectively reduce levels of ochratoxin A, a nephrotoxic and carcinogenic mycotoxin commonly found in contaminated food products, as confirmed by HPLC analysis. This dual action of direct antimicrobial effect plus toxin degradation is highly valuable for food safety.

· In Vivo Antibacterial Efficacy (2025-2026 Study): A separate 2025-2026 study using a postbiotic approach found that heat-killed P. kudriavzevii cells exhibited 89.71% in vivo inhibitory activity against Staphylococcus aureus, significantly higher than the 74.39% inhibition achieved by viable cells. This suggests that heat-killed cells (postbiotics) may be more effective and certainly safer for certain applications, as they cannot replicate or cause opportunistic infections.

3. Clinical Significance as Candida krusei (The Pathogenic Duality)

Key Virulence Factors: Biofilm formation, adhesion to epithelial cells, secretion of hydrolytic enzymes (phospholipases, proteinases), intrinsic antifungal resistance.

Clinical Manifestations: Oropharyngeal candidiasis (thrush), vulvovaginal candidiasis, candidemia (bloodstream infection), urinary tract infections (catheter-associated), invasive candidiasis in immunocompromised patients.

Actions and Clinical Relevance:

· Opportunistic Pathogen (Fifth Most Common Candida): P. kudriavzevii, in its anamorphic form Candida krusei, is recognized as the fifth most common Candida species causing human infections. It is particularly associated with immunocompromised individuals, including patients with hematologic malignancies, cancer, diabetes mellitus, those undergoing prolonged antibiotic or corticosteroid therapy, and those with indwelling medical devices such as urinary catheters. Studies have found a 26.8% incidence of P. kudriavzevii in catheterized urine samples, highlighting its clinical relevance.

· Intrinsic Fluconazole Resistance (Major Clinical Challenge): The single most important clinical feature of Candida krusei is its intrinsic resistance to fluconazole, one of the most commonly used antifungal drugs. This resistance is not acquired but inherent to the species, meaning fluconazole should never be used empirically for suspected C. krusei infections. The resistance mechanisms involve alterations in the drug target enzyme (lanosterol 14-α-demethylase) and efflux pump overexpression. Effective antifungals include ketoconazole, clotrimazole (topical), nystatin (topical), amphotericin B, and echinocandins. A 2020 study found ketoconazole was the most effective systemic agent tested (73.3% efficacy).

· Biofilm Formation on Medical Devices: P. kudriavzevii readily forms biofilms on indwelling medical devices such as urinary catheters, intravenous lines, and prosthetic heart valves. Biofilms provide a protective niche that shields the yeast from both host immune defenses and antifungal drugs, making infections difficult to eradicate and often requiring device removal.

4. Cell Wall and Microencapsulation Applications (Postbiotic Frontier)

Key Components: β-glucans, mannoproteins, chitin.

Quantitative Profile: The yeast cell wall successfully cross-linked with alginate-chitosan construct, forming particles of 47-283 nm with a zeta potential of 39.3 mV (indicating excellent stability).

Actions and Clinical Relevance:

· Controlled-Release Agent (2025-2026 Breakthrough): A 2025-2026 study demonstrated that the cell wall of P. kudriavzevii can be effectively cross-linked with alginate and chitosan to form a triple-layer microcapsule. This construct exhibited potent anti-S. aureus activity and, crucially, enabled targeted delivery and controlled release of the encapsulated bioactive agents under simulated gastrointestinal conditions. The cross-linking was confirmed by FTIR and SEM analyses. This represents a significant advancement in postbiotic technology, using the yeast's own structural components as a smart delivery vehicle.

· Immunomodulatory and Antioxidant Properties: The β-glucans in the yeast cell wall are well-known immunomodulators that can activate macrophages and enhance host immune responses. The cell wall also contributes to the overall antioxidant activity of the preparation.

An Integrated View of Healing and Application in Pichia kudriavzevii

· For Oral Health and Dental Caries Prevention (2025 Breakthrough): P. kudriavzevii represents a paradigm shift in managing dental caries. The ethyl acetate extract (PKEAE) derived from this yeast offers a multi-pronged attack on cariogenic bacteria. First, direct bactericidal action: It kills S. mutans and S. salivarius with MIC values in the low microgram range. Second, biofilm disruption: It significantly inhibits the formation of dental plaque, the biofilm that protects bacteria from clearance. Third, safety: It is non-toxic to normal oral epithelial cells. This combination of high efficacy, biofilm inhibition, and safety positions PKEAE as a compelling natural alternative to chemical mouthwashes like chlorhexidine, which can cause side effects like tooth staining and altered taste. It could be developed into a therapeutic mouthwash, toothpaste additive, or even a slow-release dental film.

· As a Probiotic and Postbiotic for Gut and Systemic Health: P. kudriavzevii functions through a sophisticated, multi-layered mechanism. First, probiotic viability: Viable cells survive gastric transit, adhere to the gut wall, and potentially modulate the gut microbiome. Second, postbiotic efficacy: Heat-killed cells retain and even enhance antimicrobial activity, with 89.71% inhibition of S. aureus in vivo, while eliminating any risk of opportunistic infection. Third, controlled release: The yeast's own cell wall can be engineered into a triple-layer microcapsule for the targeted delivery of other bioactives. Fourth, mycotoxin reduction: It reduces ochratoxin levels in food, protecting against chronic toxicity. This integrated approach, combining live probiotic effects with safer and more potent postbiotic applications, opens new frontiers in functional foods and nutraceuticals.

· For Industrial Food Fermentation and Flavor Enhancement: P. kudriavzevii is a transformative agent in the production of fermented foods and beverages. Its exceptional stress tolerance allows it to thrive where S. cerevisiae fails, particularly in high-acid, high-alcohol, and high-temperature environments like vinegar fermentation. By modulating the fungal community structure, it significantly enhances the production of fruity esters, including ethyl acetate, phenylethyl acetate, and isoamyl acetate. This results in superior aroma profiles in products like Zhenjiang aromatic vinegar. Its application can reduce the need for artificial flavorings and improve the natural quality of fermented foods.

· As a Biocontrol Agent in Agriculture: P. kudriavzevii offers a natural, sustainable alternative to chemical fungicides for controlling postharvest diseases. Its volatile organic compounds (VOCs) can inhibit fungal growth without direct contact, making it suitable for application in sealed storage environments. Its ability to degrade mycotoxins like ochratoxin adds an additional layer of food safety protection. This positions the yeast as a key player in the emerging field of biological crop protection.

Toxicological Profile and Safety Considerations

The safety of P. kudriavzevii is highly context-dependent:

As a Probiotic/Postbiotic: Isolates from fermented foods (e.g., MYSSBYPS10) have demonstrated a strong safety profile, with no hemolytic or gelatinase activity. Heat-killed cells are considered safe, as they cannot replicate. However, viable cells should be used with caution in severely immunocompromised individuals due to the potential for opportunistic infection.

As a Pathogen (Candida krusei): In immunocompromised individuals, the yeast is a significant opportunistic pathogen. It is intrinsically resistant to fluconazole, so this drug should never be used for empiric treatment. Effective antifungals include echinocandins, amphotericin B, and voriconazole. It can form biofilms on medical devices, often necessitating device removal.

General: The yeast is generally recognized as safe for industrial food fermentation purposes. However, individuals with compromised immune systems, hematologic malignancies, indwelling catheters, or those on prolonged antibiotic/corticosteroid therapy are at increased risk for infection. Pregnant and breastfeeding women should avoid probiotic supplements containing viable cells due to lack of safety data.

Conclusion: Pichia kudriavzevii (Candida krusei) is a yeast of profound duality and immense potential. It is simultaneously an industrial workhorse, a promising probiotic, a potent antimicrobial agent, and a significant opportunistic pathogen. Its exceptional multi-stress tolerance, a trait honed by evolution in diverse and harsh environments, underpins its industrial utility and probiotic viability. Recent breakthroughs in 2025 and 2026 have dramatically expanded its therapeutic horizon. The discovery of its potent antibacterial and antibiofilm activity against cariogenic oral pathogens positions it as a natural alternative for dental caries prevention. Its efficacy as a postbiotic against S. aureus and as a controlled-release agent via its own cell wall opens new frontiers in drug delivery. Its antifungal and anti-ochratoxigenic properties make it a valuable biocontrol agent for agriculture. Yet, its pathogenic potential as Candida krusei, particularly its intrinsic fluconazole resistance and biofilm-forming ability, demands respect and caution. Understanding this yeast in its full duality is essential for safely harnessing its remarkable benefits while mitigating its risks. As research continues to unlock its secrets, P. kudriavzevii is poised to become an increasingly valuable tool in biotechnology, functional foods, and even clinical therapeutics, provided it is used with appropriate context-specific safety measures.

---

Disclaimer:

Pichia kudriavzevii has a dual nature. While certain strains isolated from fermented foods are safe and possess probiotic properties, the species as a whole is also known as Candida krusei, an opportunistic fungal pathogen. This yeast is intrinsically resistant to fluconazole, a common antifungal drug. Immunocompromised individuals, those with hematologic malignancies, those on prolonged antibiotic or corticosteroid therapy, and those with indwelling catheters should avoid probiotic products containing viable P. kudriavzevii cells without professional medical supervision. Always consult a qualified healthcare professional before using this yeast for medicinal or probiotic purposes. This information is for educational purposes only and is not a substitute for professional medical advice.

---

8. Reference Books, Books for In-depth Study:

· The Yeasts: A Taxonomic Study (5th Edition) by Cletus P. Kurtzman, J.W. Fell, and Teun Boekhout

· Candida and Candidiasis (2nd Edition) by Richard A. Calderone

· Biology of Microorganisms on Grapes, in Must and in Wine by Helmut König, Gottfried Unden, and Jürgen Fröhlich

· Non-Conventional Yeasts: from Basic Research to Application by Klaus Wolf

· Yeast Biotechnology: Diversity and Applications by T. Satyanarayana and Gotthard Kunze

---

9. Further Study: Microorganisms That Might Interest You Due to Similar Properties

1. Saccharomyces cerevisiae var. boulardii

· Species: Saccharomyces cerevisiae var. boulardii | Family: Saccharomycetaceae

· Similarities: The most well-studied probiotic yeast, sharing with P. kudriavzevii applications in gut health, immunomodulation, and as a biocontrol agent. S. boulardii is considered safer and non-pathogenic, while P. kudriavzevii offers superior stress tolerance and novel antimicrobial metabolites.

2. Wickerhamomyces anomalus (Pichia anomala)

· Species: Wickerhamomyces anomalus | Family: Phaffomycetaceae

· Similarities: Another non-conventional yeast with remarkable antimicrobial properties, known for producing killer toxins and volatile organic compounds. Both species are used in food fermentation, biocontrol, and probiotic applications. W. anomalus is particularly noted for its anti-Candida activity.

3. Candida albicans

· Species: Candida albicans | Family: Saccharomycetaceae

· Similarities: The most clinically significant Candida pathogen, sharing with P. kudriavzevii (as C. krusei) the ability to cause opportunistic infections, form biofilms, and secrete hydrolytic enzymes. Unlike C. krusei, C. albicans is usually susceptible to fluconazole, making resistance management different.

4. Lactobacillus reuteri

· Species: Lactobacillus reuteri | Family: Lactobacillaceae

· Similarities: A probiotic bacterium with overlapping applications in oral health (inhibiting S. mutans), gut health, and immunomodulation. Both organisms produce antimicrobial compounds and can be used as biocontrol agents, representing the bacterial counterpart to P. kudriavzevii's yeast-based probiotic benefits.

---

-x-x-x-End-x-x-x-